| The discovery and development of rivaroxaban. | |
| | |
MedLine Citation:
|
PMID: 21434944 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Thromboembolic conditions present a considerable challenge to healthcare services because they are associated with substantial morbidity and mortality. The mainstays of prevention and treatment are anticoagulants and antiplatelet agents. Established anticoagulants have drawbacks that make their use difficult to manage and sustain. This has stimulated the search for new oral anticoagulants that are more convenient and yet still effective. This paper describes the development and future potential of rivaroxaban (Xarelto™; Bayer Schering Pharma AG, Berlin, Germany)-the first oral, direct Factor Xa inhibitor to be approved for clinical use in the prevention of venous thromboembolism in adult patients undergoing elective hip or knee replacement surgery. |
| | |
Authors:
|
Frank Misselwitz; Scott D Berkowitz; Elisabeth Perzborn |
Related Documents
:
|
8677994 - Cyclosporine and 6-mercaptopurine for active, refractory crohn's colitis in children. 17209164 - Sciatica: treatment with intradiscal and intraforaminal injections of steroid and oxyge... 23515684 - Solifenacin improves double-j stent-related symptoms in both genders following uncompli... 8456474 - Monoclonal antibodies in prophylactic immunosuppression after liver transplantation. a ... 21132024 - Fluticasone, azithromycin and montelukast therapy in reducing corticosteroid exposure i... 12006934 - Early identification of peritonitis by peritoneal cytokine measurement. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Annals of the New York Academy of Sciences Volume: 1222 ISSN: 1749-6632 ISO Abbreviation: Ann. N. Y. Acad. Sci. Publication Date: 2011 Mar |
Date Detail:
|
Created Date: 2011-03-25 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7506858 Medline TA: Ann N Y Acad Sci Country: United States |
Other Details:
|
Languages: eng Pagination: 64-75 Citation Subset: IM |
Copyright Information:
|
© 2011 New York Academy of Sciences. |
Affiliation:
|
Therapeutic Area Cardiovascular and Coagulation, Global Clinical Development, Bayer HealthCare AG, Wuppertal, Germany. Thrombosis and Hemostasis Group, Cardiovascular and Coagulation Therapeutic Area, Global Clinical Development, Bayer HealthCare Pharmaceuticals, Montville, New Jersey. Bayer HealthCare Pharmaceuticals, Cardiovascular Pharmacology, Global Therapeutic Research, Bayer HealthCare AG, Wuppertal, Germany. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The development of romiplostim for patients with immune thrombocytopenia.
Next Document: A review of the history, properties, and use of the immunomodulatory compound lenalidomide.